Search hospitals > Connecticut > Fairfield
Smilow Cancer Hospital Care Center-Fairfield
Claim this profileFairfield, Connecticut 06824
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
98 reported clinical trials
39 medical researchers
Summary
Smilow Cancer Hospital Care Center-Fairfield is a medical facility located in Fairfield, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Hospital Care Center-Fairfield is involved with conducting 98 clinical trials across 266 conditions. There are 39 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Farzana PashankarYale University7 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
32 reported clinical trials
75 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
15 reported clinical trials
24 drugs studied
Amer M. ZeidanYale Cancer Center3 years of reported clinical research
Studies Leukemia
Studies Myelodysplastic Syndrome
14 reported clinical trials
23 drugs studied
Joseph W. Kim, MDYale University8 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
12 reported clinical trials
25 drugs studied
Clinical Trials running at Smilow Cancer Hospital Care Center-Fairfield
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Cancer
Multiple Myeloma
Prostate Cancer
Squamous Cell Carcinoma
Urothelial Carcinoma
Pancreatic Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital Care Center-Fairfield?
Smilow Cancer Hospital Care Center-Fairfield is a medical facility located in Fairfield, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Hospital Care Center-Fairfield is involved with conducting 98 clinical trials across 266 conditions. There are 39 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.